[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"toxicities\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:toxicities":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100593784","a-study-of-treatment-related-toxicities-and-quality-of-life-after-local-therapy-in-chinese-breast-cancer-patients-100593784",false,"NCT07010939","A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients","A Prospective Multi-modal Cohort Study of Local Treatment-related Toxicities and Quality of Life in Chinese Breast Cancer Patients (PERSEVERE)","PERSEVERE","Inclusion Criteria:\n\n* Women aged 18 years or older\n* Diagnosed with stage I, II, or III invasive breast cancer confirmed by pathology or cytology\n* No signs of metastatic disease (cancer that has spread to other parts of the body)\n* Scheduled to receive local treatment, including:\n\nSurgery\n\nAnd\u002For neoadjuvant or adjuvant therapy such as chemotherapy, radiation, hormone therapy, or targeted therapy\n\n* Willing and able to complete health questionnaires and attend follow-up visits\n* Has given written informed consent to join the study\n\nExclusion Criteria:\n\n* Have metastatic breast cancer or local recurrence\n* Have already received curative treatment (surgery, chemo, etc.) for the current breast cancer before joining the study\n* Are currently pregnant or breastfeeding\n* Have a history of another cancer within the past 5 years (except for non-melanoma skin cancer or in-situ cervical cancer)\n* Are unable to participate in the study due to mental, physical, or legal reasons (for example, under legal guardianship or imprisonment)",true,"FEMALE","18 Years",{"count":21,"type":22},3000,"ESTIMATED","5 Years","OBSERVATIONAL","This study, called PERSEVERE, examines how local treatment for early breast cancer affects people's health and daily lives over time.\n\nPeople who join the study will have early-stage breast cancer and receive treatment such as surgery and other therapies that are used before or after surgery. The study does not include people with late-stage (metastatic) breast cancer.\n\nResearchers want to learn about short- and long-term side effects that can happen during or after treatment. These may include tiredness, trouble sleeping, emotional distress, pain, or changes in heart or lung function. The study also looks at how these effects impact participants' quality of life.\n\nParticipants will be asked to complete surveys about how they feel. They will also have health checks, such as heart tests, lung function tests, and blood samples. Tissue samples from surgery will also be collected.\n\nThe goal is to understand better how different people respond to breast cancer treatment and find ways to support long-term recovery.",[27,28,29,30],"Breast Neoplasms","Quality of Life (QOL)","Toxicities","Breast Diseases",[27,32,33,34,35],"Treatment-Related Toxicities","Quality of Life","Patient-Reported Outcomes","Prospective Study","RECRUITING","2025-09-08",{"date":39,"type":40},"2025-09-12","ACTUAL",{"date":42,"type":40},"2025-04-07",{"date":44,"type":22},"2028-12-31",{"name":46,"class":47},"FangYi","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":19,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":5},"100579836","phase-3-conditioning-regimen-of-melphalan-busulfan-and-fludarabine-a-randomized-study-of-different-dose-of-melphalan-100579836","NCT06829472","Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan","Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomize Study Comparing 100mg\u002Fm2 to 140mg\u002Fm2 Melphalan for Adult Patients With Acute Myeloid Leukemia or Myelodysplasia Syndrome.","Inclusion Criteria:\n\n* Patients with AML in first remission\n* Patients with MDS with bone marrow blast \\>5% but remain less than 20% before transplantation\n* Donor available: HLA matched sibling donor, 9\\~10\u002F10 matched unrelated donor or haplo-identical donor\n* Inform consent provided\n\nExclusion Criteria:\n\n* Patients with active infection (bacteria, fungal or viral)\n* Patients with abnormal liver, renal and cardiac function","ALL","55 Years",{"count":59,"type":22},120,"INTERVENTIONAL",[62],"PHASE3","Conditioning regimen with melphalan-busulfan and fludarabine (MBF) achieved low relapse rate in patients with acute myeloid leukemia (AML) and myelodysplasia syndrome (MDS). In our previous retrospective study, we demonstrated that melphalan dose at 100 or 140mg\u002Fm2 had similar incidence of relapse but it might had lower toxicities. In this prospective randomize study, we aim to compare the transplantation outcome in adult patients with AML\u002FMDS receiving either MBF with 100 or 140 mg\u002Fm2 melphalan.",[29,65],"Survivorship",[67],"melphalan, AML, MDS, allogeneic stem cell transplantation","2025-02-14",{"date":70,"type":40},"2025-02-17",{"date":72,"type":40},"2023-12-01",{"date":74,"type":22},"2026-12-01",{"name":76,"class":47},"Shanghai Jiao Tong University School of Medicine"]